NASDAQ:STRO

Sutro Biopharma Stock Insider Trading

Healthcare > Biotechnology

Buy STRO

*Your capital is at risk

$26.09

-2.59 (-9.03%)

At Close: Jun 05, 2026

Sutro Biopharma Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 96.61. In total, the insiders bought 2.43M and sold 66.8K STRO shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	96.61
● Buy	2.43M shares
● Sell	66.8K shares
85% Buy Activity Negligible or No Correlation
Buy Signal High Confidence Mar 02, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 96.61. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (85% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 01, 2026 Buy	Restricted Stock Units (RSUs) M-Exempt	Chung Jane Chief Executive Officer	CEO / President	688 Value: $17.9K
Mar 01, 2026 Buy	Restricted Stock Units (RSUs) M-Exempt	Chung Jane Chief Executive Officer	CEO / President	2 500 Value: $65.2K
Mar 01, 2026 Buy	Common Stock M-Exempt	Chung Jane Chief Executive Officer	CEO / President	688 Value: $17.9K
Mar 01, 2026 Sell	Common Stock F-InKind	Chung Jane Chief Executive Officer	CEO / President	1 271 Value: $26.0K
Mar 01, 2026 Buy	Restricted Stock Units (RSUs) M-Exempt	Pauling David Chief Admin. Ofcr. & GC	Officer	842 Value: $22.0K
Mar 01, 2026 Buy	Common Stock M-Exempt	Pauling David Chief Admin. Ofcr. & GC	Officer	500 Value: $13.0K
Mar 01, 2026 Sell	Common Stock F-InKind	Pauling David Chief Admin. Ofcr. & GC	Officer	551 Value: $11.3K
Mar 01, 2026 Buy	Common Stock M-Exempt	Pauling David Chief Admin. Ofcr. & GC	Officer	842 Value: $22.0K
Mar 01, 2026 Buy	Restricted Stock Units (RSUs) M-Exempt	Pauling David Chief Admin. Ofcr. & GC	Officer	500 Value: $13.0K
Mar 01, 2026 Buy	Common Stock M-Exempt	Gerber Hans-peter Chief Scientific Officer	Officer	1 125 Value: $29.4K
Mar 01, 2026 Sell	Common Stock F-InKind	Gerber Hans-peter Chief Scientific Officer	Officer	463 Value: $9K
Mar 01, 2026 Buy	Restricted Stock Units (RSUs) M-Exempt	Gerber Hans-peter Chief Scientific Officer	Officer	1 125 Value: $29.4K
Mar 01, 2026 Buy	Common Stock M-Exempt	Chung Jane Chief Executive Officer	CEO / President	2 500 Value: $65.2K
Dec 23, 2025 Buy	Stock Option (right to buy) A-Award	Chow Gregory K. CFO	C-Suite Officer	8 200 Value: $85.1K
Dec 23, 2025 Buy	Stock Option (right to buy) A-Award	Gerber Hans-peter Chief Scientific Officer	Officer	7 925 Value: $82.3K
Dec 23, 2025 Buy	Stock Option (right to buy) A-Award	Pauling David Chief Admin. Ofcr. & GC	Officer	7 200 Value: $74.7K
Dec 23, 2025 Buy	Stock Option (right to buy) A-Award	Dybbs Michael Director	Director	1 500 Value: $15.6K
Dec 23, 2025 Buy	Stock Option (right to buy) A-Award	Hunter Heidi Director	Director	1 500 Value: $15.6K
Dec 23, 2025 Buy	Stock Option (right to buy) A-Award	Jagpal Sukhi Director	Director	1 500 Value: $15.6K
Dec 23, 2025 Buy	Stock Option (right to buy) A-Award	Lobacki Joseph M Director	Director	1 500 Value: $15.6K
Dec 23, 2025 Buy	Stock Option (right to buy) A-Award	Matsui Connie Director	Director	1 500 Value: $15.6K
Dec 23, 2025 Buy	Stock Option (right to buy) A-Award	Wigginton Jon Marc Director	Director	1 500 Value: $15.6K
Dec 23, 2025 Buy	Stock Option (right to buy) A-Award	Petree Daniel H Director	Director	1 500 Value: $15.6K
Dec 23, 2025 Buy	Stock Option (right to buy) A-Award	Panek James P Director	Director	1 500 Value: $15.6K
Dec 12, 2025 Buy	Restricted Stock Unit (RSU) M-Exempt	Chung Jane Chief Executive Officer	CEO / President	2 500 Value: $24.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT SUTRO BIOPHARMA INC.

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-H...

Read Full Profile Here